HK Stock Market Move | MINIEYE (02431) rose more than 8% and won the Tongxiang unmanned vehicle project with a total amount of 11.85 million yuan.
Innovative Holdings (02431) rose more than 8%, as of the time of writing, it increased by 8% to HK$24.58, with a trading volume of HK$44.66 million.
MINIEYE (02431) rose more than 8%, as of press time rose 8%, reported at 24.58 Hong Kong dollars, with a turnover of 44.6636 million Hong Kong dollars.
On the news front, on the evening of October 19th, MINIEYE announced that the group had recently officially received the bid notification and confirmed that it had become the winning unit of the integrated city traffic perception project (2025 autonomous driving bus procurement project) in Tongxiang City, with a bid amount of 11.85 million RMB (Tongxiang unmanned vehicle project). This project marks a key breakthrough for the company in the commercialization process of L4 level autonomous driving, further consolidating the group's leading position in the field of smart cities and intelligent transportation.
According to the performance report for the first half of 2025, MINIEYE's L4 business revenue has exceeded tens of millions, with more than ten projects acquired, entering the fast lane of scale and commercial development. This Tongxiang project will help the company's L4 business revenue reach a new high. The company stated that it will continue to increase investment in core technology research and development for L4 level autonomous driving, leveraging technology iteration and scenario expansion to drive growth in new areas.
Related Articles

CHINA HK POWER(00931): Price and trading volume have fluctuated, and discussions on potential investments are still ongoing.

AstraZeneca PLC Sponsored ADR (AZN.US) breast cancer drug Enhertu has shown superior effectiveness in preventing recurrence compared to competitors, and is expected to cure early stage patients.

NETDRAGON(00777) spent HK$1.237 million to repurchase 100,000 shares on October 20th.
CHINA HK POWER(00931): Price and trading volume have fluctuated, and discussions on potential investments are still ongoing.

AstraZeneca PLC Sponsored ADR (AZN.US) breast cancer drug Enhertu has shown superior effectiveness in preventing recurrence compared to competitors, and is expected to cure early stage patients.

NETDRAGON(00777) spent HK$1.237 million to repurchase 100,000 shares on October 20th.

RECOMMEND